SCHEMBL2373930

SCHEMBL2373930

COCCN(C)C(=O)C(Cc1ccccc1)NCc1ccc(-c2ccncc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR142 Q7Z601 6/20 0.46
MME P08473 1/20 0.45
ROCK2 O75116 5/20 0.45
ROCK1 Q13464 5/20 0.45
RPS6KA5 O75582 2/20 0.45
PRKACA P17612 2/20 0.45
MAPK1 P28482 2/20 0.45
GSK3A P49840 2/20 0.45
GSK3B P49841 2/20 0.45
PRKX P51817 2/20 0.45
PRKG1 Q13976 2/20 0.45
PKN2 Q16513 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
SGK2 Q9HBY8 2/20 0.45
AKT1 P31749 2/20 0.45
MAP4K4 O95819 1/20 0.45
PRKCG P05129 1/20 0.45
RPS6KB1 P23443 1/20 0.45
PRKCD Q05655 1/20 0.45
PRKG2 Q13237 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2373927 1.00 GPR142 (0.46) GPR142MMEROCK2ROCK1RPS6KA5
SCHEMBL2374776 0.91 PPARG (0.45) MMEPPARGHDAC1CYP3A4ALDH1A1
SCHEMBL2374783 0.91 PPARG (0.45) MMEPPARGHDAC1CYP3A4ALDH1A1
SCHEMBL2375179 0.90 MME (0.44) GPR142MMEPPARGHDAC1
SCHEMBL2375171 0.90 MME (0.44) GPR142MMEPPARGHDAC1
SCHEMBL2375746 0.87 PPARG (0.44) MMEPPARGCYP3A4ALDH1A1CYP2D6
SCHEMBL2375740 0.87 PPARG (0.44) MMEPPARGCYP3A4ALDH1A1CYP2D6
SCHEMBL2374270 0.79 L3MBTL1 (0.45) ALDH1A1
SCHEMBL2374260 0.79 L3MBTL1 (0.45) ALDH1A1
SCHEMBL16254308 0.78 MMP9 (0.45) MMEALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 GPR142 3414/4885MME 1117/4885ROCK2 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.